Acute lymphoblastic leukemia with the t(17;19) translocation: hope has appeared! Multimodal immunotherapy in a 3-year-old child with refractory disease: a case report

D. V. Litvinov; Литвинов Д. В.; I. P. Tesakov; Тесаков И. П.; L. N. Shelikhova; Шелихова Л. Н.; L. A. Khachatryan; Хачатрян Л. А.; E. A. Zerkalenkova; Зеркаленкова Е. А.; Yu. V. Olshanskaya; Ольшанская Ю. В.; A. Yu. Komkov; Комков А. Ю.; A. M. Popov; Попов А. М.; E. V. Mikhaylova; Михайлова Е. В.; A. N. Remizov; Ремизов А. Н.; N. V. Myakova; Мякова Н. В.; Yu. V. Rumyantseva; Румянцева Ю. В.; A. I. Karachunskiy; Карачунский А. И.

doi:10.24287/1726-1708-2022-21-3-100-114

Acute lymphoblastic leukemia with the t(17;19) translocation: hope has appeared! Multimodal immunotherapy in a 3-year-old child with refractory disease: a case report

Authors: Litvinov D.V.¹, Tesakov I.P.¹, Shelikhova L.N.¹, Khachatryan L.A.¹, Zerkalenkova E.A.¹, Olshanskaya Y.V.¹, Komkov A.Y.¹, Popov A.M.¹, Mikhaylova E.V.¹, Remizov A.N.¹, Myakova N.V.¹, Rumyantseva Y.V.¹, Karachunskiy A.I.¹
Affiliations:
1. Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
Issue: Vol 21, No 3 (2022)
Pages: 100-114
Section: CLINICAL OBSERVATIONS
Submitted: 15.10.2022
Accepted: 15.10.2022
Published: 15.10.2022
URL: https://hemoncim.com/jour/article/view/656
DOI: https://doi.org/10.24287/1726-1708-2022-21-3-100-114
ID: 656

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Acute lymphoblastic leukemia (ALL) with translocation t(17;19)(q21-q22;p13) TCF3::HLF (E2A::HLF) accounts for less than 1% of childhood B-lineage ALL. Since the first description, patients with this type of ALL are stratified into high-risk group. The disease often has a unique clinical presentation with disseminated intravascular coagulation and hypercalcemia, that are uncommon in other types of B-lineage ALL. This type of ALL is characterized by an extremely poor prognosis despite intensive treatment and hematopoietic stem cell transplantation (HSCT) in the first remission. In the last decade, some new data on the mechanisms of leukemogenesis in this type of ALL made it possible to come closer to understanding the reasons for the high refractoriness to chemotherapeutic agents. Along with the reports on the possible effectiveness of the BCL-2 (venetoclax) and Aurora kinase A (alisertib) inhibitors in this type of ALL, cellular immunotherapy (various chimeric antigen receptor (CAR)-T cell constructs), anti-CD19 (blinatumomab) and anti-CD22 (inotuzumab ozogamicin) monoclonal antibodies appear promising in the treatment of this disease. To date, there are neither published data on direct comparisons of the effectiveness of these methods nor specific recommended therapy protocols for these patients. It is also unclear if the new therapeutic approaches can completely replace HSCT or they only increase relapse-free survival after it. Here, we review the data on this translocation published in the medical literature and present a case report of a 3-year-old boy with this type of leukemia, who did not respond to four-component induction therapy according to the ALL-MB 2015 Protocol and received anti-CD19 CAR-T therapy with the achievement of the first MRD (minimal residual disease)-negative remission, which lasted 11 months. After MRD-relapse and unsuccessful attempt at therapy with autologous CD19/CD22 CAR-T cells, the patient developed an extended isolated bone marrow relapse. He achieved the second MRD-negative remission after reinduction therapy with inotuzumab ozogomycin and received allogeneic HSCT from a related donor. At the time of writing, the patient is in complete molecular remission for 16 months after transplantation. The patient's parents have consented to the use of de-identified clinical information and photos of the patient in scientific research and publications.